Leerink Partnrs Issues Positive Estimate for NRIX Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Leerink Partnrs lifted their Q2 2025 EPS estimates for shares of Nurix Therapeutics in a report issued on Tuesday, April 8th. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings of ($0.84) per share for the quarter, up from their prior estimate of ($0.93). Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Nurix Therapeutics' current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics' Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($1.04) EPS, FY2025 earnings at ($3.54) EPS and FY2026 earnings at ($3.37) EPS.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. The firm had revenue of $18.45 million for the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same quarter last year, the firm posted ($0.76) EPS.

Other equities analysts also recently issued research reports about the stock. Stephens reissued an "overweight" rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Royal Bank of Canada increased their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 29th. Stifel Nicolaus cut their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. HC Wainwright restated a "buy" rating and set a $36.00 target price on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. Finally, Morgan Stanley boosted their price target on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a research note on Monday, February 3rd. Three research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $30.44.

Nurix Therapeutics Price Performance

Nurix Therapeutics stock traded down $0.43 during mid-day trading on Friday, reaching $9.39. 223,376 shares of the stock traded hands, compared to its average volume of 888,601. The stock has a market capitalization of $715.86 million, a PE ratio of -3.25 and a beta of 2.23. The business's 50-day moving average is $13.66 and its 200-day moving average is $19.00. Nurix Therapeutics has a 12-month low of $8.18 and a 12-month high of $29.56.

Institutional Investors Weigh In On Nurix Therapeutics

Institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its stake in Nurix Therapeutics by 32.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 30,383 shares of the company's stock valued at $683,000 after purchasing an additional 7,441 shares during the last quarter. FMR LLC increased its position in shares of Nurix Therapeutics by 675.9% in the 3rd quarter. FMR LLC now owns 586,902 shares of the company's stock valued at $13,188,000 after purchasing an additional 511,256 shares during the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of Nurix Therapeutics during the third quarter worth about $240,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Nurix Therapeutics in the 3rd quarter valued at about $346,000. Finally, Barclays PLC grew its stake in Nurix Therapeutics by 77.9% during the 3rd quarter. Barclays PLC now owns 128,344 shares of the company's stock worth $2,884,000 after buying an additional 56,190 shares during the last quarter.

Insider Activity

In other Nurix Therapeutics news, CFO Houte Hans Van sold 5,825 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now directly owns 33,724 shares of the company's stock, valued at approximately $488,660.76. The trade was a 14.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the sale, the insider now directly owns 55,937 shares in the company, valued at approximately $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,326 shares of company stock valued at $213,449 in the last ninety days. Insiders own 7.20% of the company's stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.